Free tool
Drugs in development
Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations
Drugs in development
3,685
Not FDA-approved
In Phase 3
1,424
Highest phase reached
Matching your filters
16
16 drugs in development
Names, sponsors and conditions come from the trial records. Click a drug for its trials.
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- HLX07Phase 34 trials
Shanghai Henlius Biotech · Colon Cancer Adenocarcinoma, Squamous NSCLC, Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
- HLX22Phase 34 trials
Shanghai Henlius Biotech · HER2 + Breast Cancer, HER2-low Hormone Receptor Positive Breast Cancer, Gastroesophageal-junction Cancer
- EU-sourced KeytrudaPhase 32 trials
Shanghai Henlius Biotech · Non-Squamous Non-Small Cell Lung Cancer, Non Squamous Non Small Cell Lung Cancer
- HLX87Phase 32 trials
Shanghai Henlius Biotech · HER2 + Breast Cancer
- US-sourced KeytrudaPhase 32 trials
Shanghai Henlius Biotech · Non-Squamous Non-Small Cell Lung Cancer, Non Squamous Non Small Cell Lung Cancer
- HLX04-OPhase 31 trial
Shanghai Henlius Biotech · Age Related Macular Degeneration
- HLX11Phase 31 trial
Shanghai Henlius Biotech · Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer
- HLX13Phase 31 trial
Shanghai Henlius Biotech · Hepatocellular Carcinoma (HCC)
- HLX15Phase 31 trial
Shanghai Henlius Biotech · Newly Diagnosed Multiple Myeloma
- HLX17Phase 31 trial
Shanghai Henlius Biotech · Non-Squamous Non-Small Cell Lung Cancer
- HX22Phase 31 trial
Shanghai Henlius Biotech · HER2 + Breast Cancer
- HLX01Phase 21 trial
Shanghai Henlius Biotech · Membranous Nephropathy, Lupus Nephritis (LN)
- HLX26Phase 21 trial
Shanghai Henlius Biotech · NSCLC Stage IV
- HLX53Phase 21 trial
Shanghai Henlius Biotech · Carcinoma, Hepatocellular
- HLX79Phase 21 trial
Shanghai Henlius Biotech · Membranous Nephropathy, Lupus Nephritis (LN)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.